
News|Articles|November 9, 2012
FDA fast tracks drug for metastatic breast cancer
FDA has fast-tracked etirinotecan pegol (NKTR-102) (Nektar Therapeutics) for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine (ATC).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement























